Scorpion Venom Peptide Smp24 Revealed Apoptotic and Antiangiogenic Activities in Solid-Ehrlich Carcinoma Bearing Mice

Abstract

AbstractScorpion venom contains various peptides that could be utilized to treat various diseases, including cancer. This study aimed to evaluate the anti-cancer activity of scorpion venom peptide (Smp24) using a solid Ehrlich Carcinoma (SEC) mice model. SEC model was established by subcutaneous transplantation of SEC cells into Swiss albino female mice afterward subcutaneous injection of the Smp24 peptide compared to 5-Fluorouracil (5-FU) as a standard drug. Various biochemical, hematological, histopathological, immunohistochemical, and molecular (western blotting and RT-PCR) assays were performed to evaluate the antitumor activity of Smp24. Results revealed that Smp24 peptide significantly reduced tumor volume. Interestingly, Smp24 peptide significantly restored normal body functions in cancer-treated groups by maintaining HB, RBC’s, and WBC’s levels, reducing the elevated serum ALT and AST, and increasing total protein and albumin as well as enhancing antioxidant status through reducing the level of MDA and NO and elevating GSH, SOD, and CAT levels. Moreover, it restored the normal morphology of the liver and kidney tissues and improved hematological parameters in cancer-treated animals. Smp24 induced apoptosis in SEC cells, through upregulation of caspase-3 and BAX and the downregulation of VEGF, Bcl-2, p53, PCNA, and Ki67. Moreover, results exhibited the apoptotic and antiangiogenic effects of Smp24 against SEC cancer cells. These findings supported our previous results about the anti-cancer efficacy of Smp24 and made it a good candidate for developing effective and safe anti-cancer agents.